Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Serplulimab Combined With Nab-paclitaxel and SOX as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction: A Multicenter Randomized Controlled Trial

NCT06576921 is registered in ClinicalTrials.gov with Xijing Hospital as lead sponsor.

NCT NCT06576921
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06576921 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Serplulimab Combined With Nab-paclitaxel and SOX as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction: A Multicenter Randomized Controlled Trial
Lead sponsor
Xijing Hospital
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 15, 2024
Completion date
September 30, 2026
Enrollment
116 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

immune checkpoint inhibitors, stomach neoplasms